Description

Cencora: Leveraging Strategic Partnerships & Acquisitions To Change The Game!

Cencora delivered a solid financial performance in the fourth quarter and full fiscal year of 2024, indicating a robust momentum in its pharmaceutical-centric strategy. The company reported a 15% rise in consolidated revenue, reaching $79.1 billion for the quarter, driven by growth in both the U.S. Healthcare Solutions (USHS) and International Healthcare Solutions (IHS) segments. The adjusted diluted earnings per share (EPS) also increased by 17% in the fourth quarter, contributing to a 15% rise in full-year adjusted diluted EPS, reaching $13.76.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!